Trials / Unknown
UnknownNCT05105815
Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
An Exploratory Study on the Safety and Effectiveness of Autoimmune Cell Therapy Sensitized With Liver Cancer Neoantigen in Patients With High Risk of Recurrence After Surgical Resection of Primary Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IPM001 | IPM001 will be used against tumor cells |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2021-11-03
- Last updated
- 2021-11-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05105815. Inclusion in this directory is not an endorsement.